The pain management therapeutics market is likely to witness a decline worldwide in the next five years, as reported in Transparency Market Research’s recent publication, “Pain Management Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018”.

Pain usually results from tissue damage and the severity of pain differs from person to person. Pain can be classified on the basis of the duration and pattern of occurrence along with the affected body part. Pain management aims at alleviating pain and improving the quality of life of the patients suffering from acute or chronic pain disorders. It is one of the major health concerns across the globe due to its debilitating effects and loss of productivity. Presently, various methods of pain management are available such as the use of minimally invasive pain management devices, physiotherapy and chiropractor therapy. However, pharmaceuticals that are commonly called analgesics or painkillers form the first line of treatment prescribed by the physicians. These include drugs belonging to various therapeutic classes such as anticonvulsants, antidepressants, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-migraine agents and others. The demand for pain management is high and growing in order to cater to the needs of rising number of patients with chronic pain disorders. These pain conditions in turn affect their productivity and increase the nation’s healthcare expenditure on pain management.

Request Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1059

The pain management therapeutics market is expected to witness a decline globally in the next five years due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. In addition to this, lack of novel drug formulations in pain management will also account for the dip in the growth of the overall pain management drugs market.

The NSAIDs segment was the largest revenue generator in 2011 of the total market, owing to the presence of the most commonly used OTC painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid). By indication, cancer pain and neuropathic pain were the two largest segments in 2011 of the total pain management therapeutics market due to the rising incidence rates globally of conditions such as cancer and diabetes.

The North American market for pain management therapeutics was valued at USD 21,733.3 million in the year 2011 and is expected to decline to USD 14,264.3 million by 2018, although the region is expected to continue to lead the market in terms of revenue throughout the forecast period. In terms of market growth and attractiveness, Asia-Pacific and Rest of the World (RoW) are considered the most lucrative markets for pain management drugs due to rigorous government initiatives and healthcare amendments favoring the expansion of this market. The continuous economic slowdown in Europe will further decelerate its growth and the region’s contribution to the overall market is expected to remain constant throughout the forecast period. Some of the leading players in the market for branded pain management therapeutics include Pfizer, Inc., Purdue Pharma L.P., Endo Health Solutions, Eli Lilly & Co., Johnson & Johnson and AstraZeneca PLC.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Contact us:

Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email:Â [email protected]
Website: http://www.transparencymarketresearch.com/